NEOPV-01 is under clinical development by BioNTech and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect NEOPV-01’s likelihood of approval (LoA) and phase transition for Peritoneal Cancer took place on 17 Nov 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NEOPV-01 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

NEOPV-01 overview

NEO-PV-01 is under development for the prevention of metastatic melanoma, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, metastatic nonsquamous non-small cell lung cancer (first and second line), bladder cancer, chronic lymphocytic leukemia, glioblastoma multiforme (First line therapy), follicular lymphoma and renal cell carcinoma. It is administered subcutaneously. The vaccine candidate constitutes personalized neoantigens and peptides which are derived from patient-specific immunogenic epitopes. It is given in combination with immunostimulant poly-ICLC (Polyriboinosinic-Polyribocytidylic Acid-Polylysine).

BioNTech overview

BioNTech is a biotechnology company that develops immunotherapies for cancer and infectious diseases. It is investigating mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators to treat advanced melanoma, solid tumors, non-small cell lung cancer (NSCLC), prostate, head and neck, ovarian, pancreatic and triple negative breast cancer. The company is also evaluating treatments for HIV, tuberculosis, influenza and covid-19. BioNTech utilizes FixVac and iNeST technology platforms to discover and develop cancer immunotherapies targeting antigens and neoantigens. It works in partnership with Genentech Inc, Eli Lilly and Co, Genmab AS, and other biopharmaceutical companies to develop its pipeline products. BioNTech is headquartered in Mainz, Rhineland-Palatinate, Germany.

Quick View NEOPV-01 LOA Data

Report Segments
  • Innovator
Drug Name
  • NEOPV-01
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: BioNTech
  • Originator: Broad Institute, Massachusetts General Hospital and Dana-Farber Cancer Institute
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.